Poxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral First-in-Class AMPK Activator, in NASH Dec 14, 2020
Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting® 2020 Nov 16, 2020
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2020 Oct 20, 2020
Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French Government Oct 15, 2020
Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator Oct 1, 2020
